- Home
- PSNY vs GLUE Comparison
PSNY vs GLUE Comparison
Compare PSNY & GLUE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | PSNY | GLUE |
|---|---|---|
| Founded | 2017 | 2019 |
| Country | Sweden | United States |
| Employees | N/A | N/A |
| Industry | Auto Manufacturing | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.6B | 1.4B |
| IPO Year | N/A | 2021 |
Fundamental Metrics
Financial Performance| Metric | PSNY | GLUE |
|---|---|---|
| Price | $18.44 | $17.92 |
| Analyst Decision | Sell | Strong Buy |
| Analyst Count | 2 | 4 |
| Target Price | $15.00 | ★ $29.50 |
| AVG Volume (30 Days) | 289.3K | ★ 1.1M |
| Earning Date | 03-15-2026 | 03-19-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ 0.25 |
| Revenue | ★ $2,547,619,000.00 | $181,538,000.00 |
| Revenue This Year | $49.69 | $84.02 |
| Revenue Next Year | $44.50 | N/A |
| P/E Ratio | ★ N/A | $70.99 |
| Revenue Growth | 24.82 | ★ 1112.27 |
| 52 Week Low | $11.75 | $3.50 |
| 52 Week High | $42.60 | $25.77 |
Technical Indicators
Market Signals| Indicator | PSNY | GLUE |
|---|---|---|
| Relative Strength Index (RSI) | 55.03 | 37.39 |
| Support Level | $17.65 | $18.91 |
| Resistance Level | $19.33 | $20.06 |
| Average True Range (ATR) | 1.78 | 1.32 |
| MACD | 0.07 | -0.54 |
| Stochastic Oscillator | 72.79 | 2.36 |
Price Performance
Historical ComparisonAbout PSNY Polestar Automotive Holding UK PLC ADS
Polestar Automotive Holding UK PLC operates as an electric vehicle manufacturer. It engages in designing products that are engineered to excite consumers and drive change. Polestar defines market standards in design, technology, and sustainability. Polestar was established as a premium electric car brand by Volvo Cars and Geely Holdings. Polestar has produced two electric performance cars, namely Polestar 1 and Polestar 2. Geographically, it derives a majority of revenue from the United Kingdom.
About GLUE Monte Rosa Therapeutics Inc.
Monte Rosa Therapeutics Inc is a biotechnology company that specializes in developing molecular glue degraders (MGDs), a class of small molecule drugs that leverage the body's natural protein destruction mechanisms to selectively degrade therapeutically-relevant proteins. Utilizing the QuEEN platform, the company employ artificial intelligence and proprietary experimental tools to identify target proteins for degradation by MGDs. With a diverse library of over 50,000 MGD molecules, their product candidate, MRT-2359, targets the translation termination factor protein GSPT1 for potential use in MYC-driven tumors. The company's focus lies in advancing its pipeline of MGDs, aiming to provide novel therapeutic modalities for various diseases.